Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot phase IV study of degarelix effects on body composition and bone mineral density in prostate cancer without bone metastasis
2016-004210-10Phase 4Completed
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Nov 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of degarelix in prostate cancer (PCa), sponsored by ASST Spedali Civili di Brescia. Primary endpoint: Change in fat body mass at 12 months. Started Nov 2020; status: completed.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2016-004210-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004210-10.